



To the European Patent Office

## Entry into the European phase (EPO as designated or elected Office)

European application number	EP04819600.0
PCT application number	PCT/EP2004/013162
PCT publication number	WO05054209
Applicant's or representative's reference	PRD2124-PCT-EPO

### 1. Applicant

Particulars of the applicant(s) are contained in the international publication or were recorded by the International Bureau subsequent to the international publication.



Changes which have not yet been recorded by the International Bureau are set out here:



Address for correspondence

### 2. Representative 1

This is the representative who will be listed in the Register of European Patents and to whom notifications will be made  
Name

Vermuyten, K.

Address of place of business

Janssen Pharmaceutica N.V.  
Turnhoutseweg 30  
B-2340 Beerse  
Belgium

Telephone

+ 32 14 60 35 99

Fax

+ 32 14 60 54 91

e-mail

patents@janbe.jnj.com

Any additional representative(s) is/are listed here:



### 3. Authorisation

An individual authorisation is attached.



A general authorisation has been registered under No:



4736

A general authorisation has been filed, but not yet registered.



The authorisation filed with the EPO as PCT receiving Office expressly includes the European phase.



### 4. Request for examination

Examination of the application under Art. 94 EPC is hereby requested. The examination fee is being (has been, will be) paid.



Request for examination in an admissible non-EPO language:



Verzocht wordt om onderzoek van de aanvraag als bedoeld in Art. 94.

---

## 5. Copies

One or more additional sets of copies of the documents cited in the supplementary European search report are hereby requested.

☐

Number of additional sets of copies

---

## 6. Documents intended for proceedings before the EPO

6.1 Proceedings before the EPO as designated Office (PCT I) are to be based on the following documents:

the application documents published by the International Bureau (with all claims, description and drawings), where applicable with amended claims under Art. 19 PCT

☒

unless replaced by the amendments attached.

☐

*Where necessary, clarifications should be attached as 'Other Documents'*

6.2 Proceedings before the EPO as elected Office (PCT II) are to be based on the following documents:

the documents on which the international preliminary examination report is based, including any annexes

☒

unless replaced by the amendments attached.

☐

*Where necessary, clarifications should be attached as 'Other Documents'*

If the EPO as International Preliminary Examining Authority has been supplied with test reports, these may be used as the basis of proceedings before the EPO.

☒

---

## 7. Translations

Translations in one of the official languages of the EPO (English, French, German) are attached as crossed below:

\* In proceedings before the EPO as designated or elected Office (PCT I + II):

Translation of the international application (description, claims, any text in the drawings) as originally filed, of the abstract as published and of any indication under Rule 13bis.3 and 13bis.4 PCT regarding biological material

☐

Translation of priority application(s)

☐

It is hereby declared that the international application as originally filed is a complete translation of the previous application (Rule 38(5) EPC)

☐

\* In addition, in proceedings before the EPO as designated Office (PCT I):

Translation of amended claims and any statement under Art. 19 PCT, if the claims as amended are to form the basis for the proceedings before the EPO (see Section 6).

☐

\* In addition, in proceedings before the EPO as elected office (PCT II):

Translation of annexes to the international preliminary examination report

☐

---

## 8. Biological material

The invention relates to and/or uses biological material deposited under Rule 28 EPC. ☐

The particulars referred to in Rule 28(1)(c) EPC (if not yet known, the depository institution and the identification reference(s) [number, symbols, etc.] of the depositor) are given in the international publication or in the translation submitted under Section 7 on: ☐

page(s) / line(s)

A copy of the receipt(s) of deposit issued by the depository institution

is attached ☐

will be filed at a later date ☐

A waiver of the right to an undertaking from the requester pursuant to Rule 28(3) EPC is attached. ☐

---

## 9. Nucleotide and amino acid sequences

The items required under Rules 5.2 and 13ter PCT and Rule 111(3) EPC have already been furnished to the EPO. ☐

The sequence listing as part of the description is attached in PDF format. ☐

The sequence listing does not include matter that goes beyond the content of the application as filed. ☐

In addition, the sequence listing data is attached in computer-readable form in accordance with WIPO Standard 25. ☐

The sequence listing data in computer-readable form in accordance with WIPO Standard 25 is identical to the sequence listing in PDF format. ☐

---

## 10. Designation fees

10.1 It is currently intended to pay seven times the amount of the designation fee. The designation fees for all the EPC contracting states designated in the international application are thereby deemed to have been paid (Art. 2 No. 3 RFees). ☒

AT BE BG CH&LI CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR

10.2 The declaration in No. 10.1 does not apply. Instead, it is currently intended to pay fewer than seven designation fees for the following EPC contracting states designated in the international application: ☐

It is requested that no communications under Rule 108(3) EPC be issued in respect of any contracting states not indicated.

10.3 If an automatic debit order has been issued (Section 12), the EPO is authorised, on expiry of the basic period under Rule 107(1)(d) EPC, to debit seven times the amount of the designation fee. If states are indicated in No. 10.2, the EPO will debit designation fees for those states only, unless instructed otherwise before the basic period expires. ☒

---

**11. Extension of the European patent**

This application is also considered as being a request for extension to all the non-contracting states to the EPC designated in the international application with which "extension agreements" were in force on the date of filing the international application. However, the extension only takes effect if the prescribed extension fee is paid.



It is currently intended to pay the extension fee for the following states:

AL HR LV MK

**12. Automatic debit order**

Currency

EUR

The EPO is hereby authorised, under the Arrangements for the automatic debiting procedure, to debit from the deposit account below any fees and costs falling due. For designation fees, see "States". The EPO is also authorised, on expiry of the basic period for paying the extension fees, to debit those fees for each of the "extension states" indicated in "States".

Deposit account number  
Account holder

28020034  
Janssen Pharmaceutica N.V.

**13. Reimbursements (if any) should be made to the following EPO deposit account:**

Number and account holder

28020034, Janssen Pharmaceutica N.V.

**14. Fees**

		Factor/Reduction applied	Fee schedule	Amount to be paid
14-1	002 Search fee	0	1 000.00	0.00
14-2	005 Designation fee	7	80.00	560.00
14-3	006 Examination fee (Euro-PCT without supplementary European search report)	1 (80%)	1 490.00	1 192.00
14-4	015 Claims fee	3	45.00	135.00
14-5	020 Basic national fee for an international application	1	95.00	95.00
14-6	033 Renewal fee for the 3rd year	1	400.00	400.00
14-7	402 Extension fee LT	1	102.00	102.00
14-8	403 Extension fee LV	1	102.00	102.00
14-9	404 Extension fee AL	1	102.00	102.00
14-10	406 Extension fee MK	1	102.00	102.00
14-11	409 Extension fee YU	1	102.00	102.00
<b>Total:</b>			<b>EUR</b>	<b>2 892.00</b>

---

**15. Annotations****15-1. Note (for EPO) (EP Phase)**

Extension States (Vermuyten K.;  
18/May/2006)  
Lithuania, Serbia and Montenegro can not  
be selected in the Extension States box.  
Croatia can not be selected in the extension  
fees. We will pay the extension fee for AL,  
HR, LV, LT, MK and YU.

---

**16. Signature(s) of applicant(s) or representative**

Place: **Beerse**  
Date: **18 May 2006**  
Signed by: **Subject: BE, Janssen Pharmaceutica N.V., K. Vermuyten 1815**  
**Issuer: , European Patent Office, European Patent Office CA**  
Capacity: **( Representative )**

For employees (Art. 133(3) EPC) having a general authorisation:  
General authorisation No. .

---



Europäisches  
Patentamt

European  
Patent Office

Office européen  
des brevets

### Acknowledgement of receipt

We hereby acknowledge receipt of the form for entry into the European phase (EPO as designated or elected Office) as follows:

Submission number	121489	
PCT application number	PCT/EP2004/013162	
Date of receipt	18 May 2006	
Receiving Office	European Patent Office, The Hague	
Your reference	PRD2124-PCT-EPO	
Applicant		
Country		
Documents submitted	package-data.xml application-body.xml	ep-euro-pct.xml EPF1200.PDF (5 p.)
Submitted by	Vermuyten, K. Subject: BE, Janssen Pharmaceutica N.V., K. Vermuyten 1815; Issuer: , European Patent Office, European Patent Office CA	
Method of submission	Online	
Date and time receipt generated	18 May 2006, 10:36:29 (CEST)	
Digest	5C:A3:CC:4E:94:2F:09:2B:15:21:56:64:84:35:BA:2D:0E:C1:4A:F2	

/European Patent Office/